The Patent Finder
SP

Supernus Pharmaceuticals, Inc.

Filings on record here from 2001, where this site's data begins
OverviewNotableFeesChangesFamiliesPatent listSources & methods

64 patents currently held

2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
13 more records may belong here and await a decision; they are not counted.

The next term ends in Apr 2027. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
26
Ending by 2030
Apr 2027
Next term end
18
Patent families

When these terms end

Held patents by the year their term ends
notable patents fee due within 90 days all others Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 2 fees due Dec 11 to 20, 2026 · next Dec 11
  • 1 fee due Jan 11, 2027
    The maintenance fee for Polymorphic Compounds and Uses Thereof (US 11,697,633) comes due Jan 11, 2027. Unpaid by Jul 12, 2027, it lapses early.
  • 1 fee due Feb 15, 2027
    The maintenance fee for METHODS OF TREATMENT USING AN mTORC1 MODULATOR (US 11,723,890) comes due Feb 15, 2027. Unpaid by Aug 16, 2027, it lapses early.
  • 1 fee due Mar 17, 2027
    The maintenance fee for Modulators of SESTRIN-GATOR2 Interaction and Uses Thereof (US 10,414,782) comes due Mar 17, 2027. Unpaid by Sep 17, 2027, it lapses early.
  • 1 fee due Aug 27, 2027
    The maintenance fee for Method of Treatment of CNS Disorders (US 11,911,368) comes due Aug 27, 2027. Unpaid by Feb 28, 2028, it lapses early.
  • 1 fee due Sep 5, 2027
    The maintenance fee for Derivatives of Substituted Morpholines and Uses Thereof (US 11,919,889) comes due Sep 5, 2027. Unpaid by Mar 6, 2028, it lapses early.
  • 1 fee due Oct 23, 2027
    The maintenance fee for Process of Making Derivatives of Substituted Morpholines (US 11,964,951) comes due Oct 23, 2027. Unpaid by Apr 24, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 2 of the patents on this record were granted since Aug 17, 2026

What they patent

The 5 largest of its 18 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.
PatentTitleStatusExpiresConfidence
US 10,154,965Osmotic Drug Delivery System
In force
 · Medium confidence
In forceMedium confidence
US 7,722,898Modified-Release Preparations Containing Oxcarbazepine and Derivatives Thereof
In force
 · High confidence
In forceHigh confidence
US 8,821,930Modified Release Preparations Containing Oxcarbazepine and Derivatives Thereof
In force
 · Medium confidence
In forceMedium confidence
US 9,119,791Modified Release Preparations Containing Oxcarbazepine and Derivatives Thereof
In force
 · Medium confidence
In forceMedium confidence
US 9,119,792Modified Release Preparations Containing Oxcarbazepine and Derivatives Thereof
In force
 · Medium confidence
In forceMedium confidence
US 9,351,975Modified Release Preparations Containing Oxcarbazepine and Derivatives Thereof
In force
 · Medium confidence
In forceMedium confidence
US 9,370,525Modified Release Preparations Containing Oxcarbazepine and Derivatives Thereof
In force
 · Medium confidence
In forceMedium confidence
US 9,855,278Modified Release Preparations Containing Oxcarbazepine and Derivatives Thereof
In force
 · Medium confidence
In forceMedium confidence
US 10,220,042Modified Release Preparations Containing Oxcarbazepine and Derivatives Thereof
In force
 · Medium confidence
In forceMedium confidence
US 11,166,960Modified Release Preparations Containing Oxcarbazepine and Derivatives Thereof
In force
 · Medium confidence
In forceMedium confidence
10 of 64 patents shown.
Pro members see all 64.
Pro members: see all 64 patents
Also on record, not counted in the 64: 2 patents in force now held by others · 25 patents ended · 18 applications pending · 51 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited